Get startedLog in
    Picture of Intelgenx Technologies logo

    IGX — Intelgenx Technologies News Story

    0.000.00%
    ca flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapMomentum Trap
    All News

    Brief: Intelgenx Enters Into Amended And Restated License Agreement With Tetra Bio-Pharma For Adversa Mucoadhesive Delivery Technology For Dronabinol

    Picture of Intelgenx Technologies logoIntelgenx Technologies
    21/10/2020 12:10
    Oct 21 (Reuters) - Intelgenx Technologies Corp  IGX.V :
    * INTELGENX ENTERS INTO AMENDED AND RESTATED LICENSE
AGREEMENT
WITH TETRA BIO-PHARMA FOR ADVERSA® MUCOADHESIVE DELIVERY
TECHNOLOGY FOR DRONABINOL
    * INTELGENX TECHNOLOGIES - TETRA BUYING WORLDWIDE ADVERSA
TECHNOLOGY RIGHTS AS IT RELATES TO PPP-002 DRUG PRODUCT
CANDIDATE FOR 3 UNDISCLOSED MILESTONE PAYMENTS
    * INTELGENX TECHNOLOGIES CORP - TETRA WILL PAY CO LOW SINGLE
DIGIT
ROYALTY ON FUTURE NET SALES OF DRONABINOL MUCOADHESIVE TABLETS

Source text for Eikon:  ID:nGNX9fjsV 
Further company coverage:  IGX.V 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Intelgenx Technologies

    See all news